YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

Soft Tissue Sarcoma Clinical Trial

Official title:

YONDELIS(Trabectedin) Single Patient Compassionate Use / Expanded Access in Soft Tissue Sarcoma

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT01427582
• Other study ID #: 05- EAP- STS
• Status: No longer available
• Phase: N/A
• First received: August 30, 2011
• Last updated: August 30, 2011

Study information

• Verified date: August 2011
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Expanded Access

Clinical Trial Summary

The YONDELIS (trabectedin) Single Patient Compassionate Use /Expanded Access program provides patients with advanced soft tissue sarcoma, who do not qualify for ongoing clinical trials with YONDELIS (trabectedin), access to this investigational treatment.

Description:

The single patient treatment instructions for use are intended for a single patient with advanced soft tissue sarcoma. The patient will be treated with YONDELIS® (trabectedin) i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days, provided that he/she fulfills all eligibility criteria.

The patient may continue to receive therapy until there is evidence of disease progression or unacceptable toxicity. Safety will be evaluated and serious adverse events will be reported. Disease assessments will occur according to institutional practice.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent.

2. 18 years-of-age or older.

3. Unresectable, advanced or metastatic, histologically proven soft tissue sarcoma.

4. Recovery from toxic effects of prior therapies to NCI CTC Grade 1 or better.

5. Hematologic variables:

• Hemoglobin =9 g/dL

• ANC =1,500/µL

• Platelet count =100,000/µL

6. Serum creatinine = upper limit of normal (ULN)

7. Hepatic function variables:

• Total bilirubin = ULN

• Total alkaline phosphatase = ULN, or if > ULN, then alkaline phosphatase liver fraction or 5'-nucleotidase must be = ULN.

• AST (serum aspartate transaminase [SGOT]) and ALT (serum alanine transaminase [SGPT]) must be = 2.5xULN

• Albumin =2.5 g/dL

Exclusion Criteria:

1. Pregnant or breast-feeding women, or patients (male or female) not employing adequate contraception. Acceptable means of birth control include IUD, oral contraceptive, subdermal implant, and a condom with a contraceptive sponge or suppository.

2. Less than 4 weeks from last dose of systemic cytotoxic therapy, radiation therapy, or therapy with any investigational agent

3. Active viral hepatitis or chronic liver disease

4. Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias

5. Active infection

Study Design

N/A

Related Conditions & MeSH terms

• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• Trabectedin
Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days

Locations

Country	Name	City	State
United States	University of Texas Southwestern	Dallas	Texas

Sponsors (2)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Country where clinical trial is conducted

United States,